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Abstract
Recurrent hepatitis C (HCV) after liver transplantation (LT) is an important cause of morbidity and mortality. Antiviral treatment is
recommended to avoid unfavorable outcomes. Direct-acting antivirals (DAA) have transformed HCV treatment, with higher
efficacy and fewer side-effects than interferon-based therapies traditionally used. To evaluate DAA treatment outcomes at a
Brazilian transplant unit, data of patients who finished HCV treatment at the Liver Transplant Unit of the University of Campinas
were analyzed. Treatment consisted of sofosbuvir, daclatasvir, and ribavirin, for 12 or 24 weeks, according to the national
guidelines. Fifty-five patients completed antiviral treatment and 54 had HCV-viral load results available. The majority of patients
were male (78%), 58 years old on average, 65% had hepatocellular carcinoma (HCC) before LT, and 67% were interferon
treatment-experienced. Most patients had HCV genotype 1 (65%), 35% had genotype 3, and started treatment on an average of
38 months after LT (range: 2–228). Fifty-eight percent were treated for 12 weeks and 42% for 24 weeks, using a mean dose of
ribavirin of 10.1 mg/kg (4.2–16.1). There were no treatment interruptions due to serious side effects. The sustained virological
response rate was 98%. Only one patient relapsed, a genotype 3 cirrhotic treated for 12 weeks. The average follow-up after
starting antivirals was 20 months. There were no recurrences of HCC, but there was one rejection episode and one cirrhosis
decompensation episode, both 12 weeks after treatment. DAA treatment is safe and effective in the post-LTsetting and was not
associated to HCC recurrence in the cohort studied.
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Introduction
Hepatitis C virus (HCV) is the main cause of liver
transplantation (LT) worldwide and has universal recur-
rence (1,2). If untreated, it can lead to cirrhosis and graft
loss in one third of patients within five years of LT, which
justifies the reduced survival rates observed when
comparing HCV to other causes of LT (2). The progres-
sion of liver fibrosis is accelerated in the post-LT
population (3) and its treatment is considered a priority,
since antiviral therapy can be used to prevent liver
damage and, consequently, prolong survival (4–6). The
achievement of sustained virological response (SVR) is
related to both histological and clinical improvement (4,6).
Therapeutic options, once dependent on interferon and
reaching 30% SVR rates, are now based on direct acting
antivirals (DAA), drugs with better tolerability, reduced side
effects, and optimized response rates, with overall SVR
rates post-LT higher than 90% (7–14). The optimal drug
regimen, duration, and timing of treatment are the issues
faced by physicians in the DAA era.
Material and Methods
This was a retrospective observational study per-
formed at the Liver Transplant Unit of the University of
Campinas.
Patients
The study included patients who were at least 18 years
old, submitted to deceased-donor orthotopic liver trans-
plantation due to complications of chronic hepatitis C
infection (end-stage liver cirrhosis or hepatocellular
carcinoma) with positive HCV viral load (HCV-VL), who
started antiviral treatment with DAA from December 1st
2015 until December 31st 2017.
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The exclusion criteria were: severe chronic kidney
disease (defined by glomerular filtration rate o30 mL 
min-1  (1.73 m2)-1, calculated with the MDRD formula),
active neoplasia, anemia (hemoglobin levels o10 g/dL),
arrhythmia, and severe or decompensated clinical comor-
bidities (defined as concomitant diseases that could lead
to poor treatment adherence or treatment discontinua-
tion, such as decompensated diabetes, recent stroke,
unstable angina, and ischemic heart disease).
Antiviral therapy
Antiviral treatment consisted of the combination of
400 mg sofosbuvir (SOF) daily, 60 mg daclatasvir (DCV)
daily, and ribavirin (RBV, doses ranging from 250 to 1250 mg
daily), for 12 or 24 weeks, according to the Brazilian hepatitis
C treatment guidelines published in 2015 (15).
Ribavirin doses were at the discretion of the attending
physician and could be reduced in case of hemolytic
anemia. Erythropoietin could be used in doses up to
40,000 IU weekly, especially for symptomatic patients with
hemoglobin levels o10 g/dL. Safety was evaluated in all
patients at least monthly during treatment and at four and
12 weeks after the end of treatment (EOT).
Antiviral efficacy was assessed with the detection
of HCV-VL at baseline, at weeks 4, 12, and 24 weeks of
treatment, and at 12 and 24 weeks after treatment.
Serum HCV-RNA viral loads were measured with the
Abbott Real Time HCV Test (USA) with a lower limit of
quantification of 12 IU/mL. Rapid virological response
was characterized by undetectable HCV-VL at treatment
week 4 and SVR was defined as undetectable HCV-VL
12 weeks after EOT.
Immunosuppression
Immunosuppression was managed according to the
local guidelines (16), usually consisting of corticosteroids
(generally withdrawn within 6 months after LT) and a calci-
neurin inhibitor as the main immunosuppressive agent
(cyclosporine or tacrolimus), at times associated to
mycophenolate. The main immunosuppressive agent was
not changed to start antiviral treatment. Patients on
prednisone had its dose tapered, if possible, at the
beginning of antiviral treatment and mycophenolate was
discontinued whenever possible, due to increased risk
of anemia when associated with RBV.
Data collection
Data regarding demographic, clinical, virological, and
treatment-related variables were collected from the patient
records using a standardized form.
Statistical analysis
Continuous variables are reported as medians and
ranges and categorical data as percentages. A P value of
o0.05 was considered significant. All analyses were
performed using EpiInfo 7.1.5.2 (CDC, USA). All patients
who fulfilled the inclusion criteria and received at least one
dose of medication during the study period were included
in the safety statistical analysis. Efficacy was assessed in
all patients who completed treatment and had HCV-VL
tested 12 weeks after EOT.
Ethical considerations
The study was approved by the local Ethics Commit-
tee. A standardized informed consent issued by the
Brazilian Ministry of Health was obtained for each patient
who started antiviral treatment, in accordance with the
2015 Brazilian hepatitis C treatment guidelines.
Results
From December 1st 2015 to December 31st 2017,
55 patients received HCV antiviral treatment at the Liver
Transplant Unit of the State University of Campinas and
fulfilled the inclusion criteria for the study. One patient was
excluded due to chronic kidney disease with a glomerular
filtration rate (GFR) of less than 30 mL min-1  (1.73m2)-1
and one patient was excluded because he was diagnosed
with metastatic squamous cell carcinoma and discontin-
ued antiviral treatment.
Demographic and baseline characteristics
Most patients were male (78%), with a median age of
58 years (Table 1). The majority of patients (36 patients,
65%) had HCV genotype 1 and 35% had genotype 3
infection. There were no infections by genotypes 2, 4, 5,
or 6. Most patients were interferon treatment-experienced
(37 patients, 67%), either before (53%) or after LT (25%).
All patients were DAA naive. Median baseline viral load
was 1,315,445 IU/mL (range: 2,297–18,500,000).
Fibrosis staging prior to antiviral therapy was not
routinely performed. According to the national treatment
guidelines (15), post-LT patients should be treated
regardless of the fibrosis level, and staging information
is not required for access to treatment. Among the
patients studied, liver biopsy was performed only when
there was evidence of elevated transaminases, in order
to differentiate HCV inflammatory activity from graft
rejection. Twenty-three patients (42%) had been biop-
sied during the last two years before treatment: 26% had
mild fibrosis (Metavir F1), 43% had moderate fibrosis (F2),
9% F3, and 4% F4. Three biopsies (13%) had histological
signs of steatosis and three patients had features of acute
rejection (which had already been managed by the moment
antiviral treatment was started).
Thirteen patients (24%) had chronic kidney disease,
with GFR between 30–60 mL min-1  (1.73m2)-1 and 25
patients (45%) had diabetes mellitus. Two patients had
undergone liver and kidney transplantation. Personal
history of hepatocellular carcinoma (HCC) before LT was
present in 36 patients (65%). No patients had HIV or
hepatitis B coinfection.
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Immunosuppression was managed according to local
guidelines and most patients were on tacrolimus- (40
patients, 73%) and/or everolimus-based regimens (12
patients, 22%). One patient did not use any immuno-
suppressive medication due to chimaerism.
Antiviral treatment characteristics
Interferon-free antiviral treatment was started at a
median of 38 months after LT (Table 2) and most patients
(58%) were treated for 12 weeks with a combination of SOF,
DCV, and RBV. The most common dosage of RBV was
750 mg daily (64% patients), with a median of 10.1 mg/kg
body weight.
Antiviral treatment side effects
Antiviral treatment was generally safe and well
tolerated. Anemia was the most common side effect
(65%), with 11 patients (20%) reaching hemoglobin levels
under 10 g/dL. Forty-five percent of patients required RBV
dose reduction, 11% used erythropoietin, and 3 received
blood transfusions for management of anemia. Hyperbili-
rubinemia (characterized by serum bilirubin levels over
2 mg/dL) occurred in 18% of patients, without need for any
intervention.
There were no treatment interruptions due to DAA-
related adverse events. Only one patient required
treatment interruption, at week 11, because he was
diagnosed with disseminated Mycobacterium tuberculo-
sis infection and the concomitant use of SOF/DCV and
rifampicin is contraindicated due to deleterious drug
interactions.
There was no diagnosis of rejection during antiviral
treatment. Twenty (36%) patients underwent changes in
the immunosuppressive medication, mostly tapering and
suspension of prednisone or mycophenolate (Table 3).
Table 1. Patient demographics and baseline characteristics.
Variable n = 55













Before LT 29 (53)
After LT 14 (25)
Anemia, n (%) 12 (22)
Chronic kidney disease, n (%) 13 (24)
Diabetes mellitus, n (%) 25 (45)










HCV: hepatitis C virus; LT: liver transplantation; HCC: hepatocel-
lular carcinoma.
Table 2. Antiviral treatment characteristics.
Variable n = 55
Time from LT to treatment, months, n (range) 38 (2–228)
Duration, n (%)
12 weeks 32 (58)
24 weeks 23 (42)
RBV dose at baseline, n (%)
250 mg 1 (2)
500 mg 5 (9)
750 mg 34 (62)
1000 mg 8 (14)
1250 mg 7 (13)
RBV dose at baseline, mg/kg, n (range) 10.1 (4.2–16.1)
HCV-VL at baseline, IU/mL, median (range) 1,315,445 (2,297–18,500,000)
Undetectable HCV-VL at week 4, n (%) 28 (51)
LT: liver transplantation; RBV: ribavirin; HCV: hepatitis C virus; VL: viral load.
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Treatment outcomes
Fifty-one percent of treated patients had a rapid
virological response (RVR), with undetectable HCV-VL
at week 4. The SVR rate observed was 98% (53/54). One
patient was lost to follow-up after EOT and there was no
HCV-VL result available to evaluate virological response.
There was only one treatment relapse, diagnosed at
week 4 post-treatment. The patient was a 61-year-old
Caucasian woman, with HCV genotype 3 infection and
Child-Pugh A cirrhosis, previously interferon-experienced.
The patient was treated with SOF/DCV/RBV for 12 weeks,
according to the Brazilian guidelines at that moment. The
patient began treatment using RBV 750 mg daily, 7.7 mg/kg,
but had its dose reduced and eventually suspended
its use at the eighth week due to severe anemia. The
baseline HCV-VL was 1,315,445 IU/mL (6.12 log). The
patient had undetectable HCV-VL at treatment week 4
(RVR), but relapsed at weeks 4 and 12 post-treatment,
when HCV-VL results were, respectively, 9,470,000 IU/mL
(log 6.98) and 24,800,000 IU/mL (log 7.4).
There is a concern regarding potential kidney toxicity
for patients treated with SOF. Among the 54 patients who
finished treatment and had SVR12 results the median
glomerular filtration rate (GFR) was 71.6 mL min-1 
(1.73m2)-1 at the beginning of treatment and 74 mL min-1 
(1.73m2)-1 12 weeks after EOT. Both patients with kidney
and liver transplantation had stable GFR during and after
antiviral treatment.
The median follow-up period after the beginning of
treatment was 20 months (range: 10–31). There was no
diagnosis of recurrence of HCC since the beginning of
antiviral treatment. Among the study population there was
one rejection episode detected 12 weeks after EOT,
managed with adjustment of tacrolimus dosage. One
patient had cirrhosis decompensation, with esophageal
variceal bleeding, ascites, encephalopathy, and jaundice
occurring twelve weeks after EOT (Table 4).
Discussion
This real-life study in Brazilian liver transplant recipi-
ents confirmed the results of international clinical trials,
demonstrating the dramatic improvement in SVR rates
that DAA therapy has brought compared to traditional
interferon-based therapy. SOF, an NS5B inhibitor, and
DCV, an NS5A inhibitor, were among the first DAA
available for interferon-free treatment worldwide.
The Brazilian hepatitis C guidelines published in 2015
(15) recommended the use of SOF associated to DCV or
simeprevir, with or without RBV to treat patients with
recurrent HCV. The attending physicians at the Liver
Transplant Unit opted for treatment of all patients with DCV,
instead of simeprevir, due to fewer drug-drug interactions
with immunosuppressants (17,18).
The ALLY-1 trial evaluated 53 post-LT patients treated
with SOF, DCV, and RBV for 12 weeks (9). Ribavirin was
used at a lower dosage (480 mg on average) than in the
present study and five patients discontinued the drug
due to side effects. The overall SVR rate was similar to
the current study, 94% (50/53 patients), 95% among
genotype 1 patients (39/41), and 91% (10/11) among
genotype 3 patients. The HCV-Target study also evaluated
the use of SOF and DCV, with or without RBV, with a similar
overall SVR rate of 96.6% among LT patients (10). Another
Brazilian cohort of 39 patients treated with SOF and DCV,
with or without RBV, for 12 weeks, reached an overall SVR
rate of 89.7%. (19). All treatment failures were genotype
3-infected patients, similar to the present study. A German
real-life study including ten patients treated with SOF and
DCV, with or without RBV, achieved 100% SVR (20).
Favorable results can also be obtained with other DAA
combinations, such as ombitasvir/paritaprevir/ritonavir and
dasabuvir/ledipasvir/SOF or simeprevir and SOF, with or
without RBV. The SVR rates achieved in clinical studies
range from 80 to 100% (10–14,20).
Table 3. Adverse effects of antiviral treatment.
Variable n = 55
Anemia
Hbo12.5 g/dL 36 (65%)
Hbo10.0 g/dL 11 (20%)
Hyperbilirubinemia 10 (18%)
Management of adverse events
Reduction of RBV dose 25 (45%)
Suspension of RBV 3 (5%)
Erythropoietin use 6 (11%)
Rejection during DAA treatment 0
Change in immunosuppressive medication 20 (36%)
Tapering of prednisone 6 (11%)
Reduction of mycophenolate 1 (2%)
Suspension of mycophenolate 4 (7%)
Switch from EVR to FK 2 (4%)
Reduction of FK dosage 4 (7%)
Increase of FK dosage 4 (7%)
Data are reported as n and percent within parentheses. Hb:
hemoglobin; RBV: ribavirin; DAA: direct-acting antiviral; FK:
tacrolimus; EVR: everolimus.
Table 4. Antiviral treatment outcomes.
Variable n = 54
SVR, n (%) 53 (98%)
Follow-up, months, n (range) 20 (10–31)
HCC recurrence, n (%) 0%
Rejection after DAA treatment, n (%) 1 (2%)
SVR: sustained virological response; HCC: hepatocellular carci-
noma; DAA: direct-acting antiviral.
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The high treatment response rates are accompanied
by relatively low frequencies of adverse events, which can
be managed with less difficulties (8–10). In our study,
there were no treatment discontinuations due to adverse
effects and the literature shows reduced rates of treatment
discontinuation, ranging from 1.7–2% (9,10). Suspension
of ribavirin due to anemia was 5% in the present study and
8% in the ALLY-1 study (9).
The recurrence of HCC, an important cause of
concern (21), was not observed in the population studied,
concurring with several papers in the literature (22–27),
but in contrast to reports of non-LT patients (28–31) that
raised concern of the possibility of HCC induced by DAA-
therapy. Conti et al. (28) evaluated 344 patients treated
with DAA and after 24 weeks of follow-up it was observed
that 7.6% of patients had HCC, affecting 28.8% of patients
with and 3% of those without previous HCC.
Another unique factor involving LT patients is the
occurrence of graft rejection. The rates observed in the
present study with DAA were dramatically lower than a
previous study at the same institution with interferon-
based therapy (0 vs 48.6% of patients treated, with 38.9%
of the rejection episodes considered to be related to
interferon therapy) (32). The only rejection case (2% of
the 55 patients included) was diagnosed 12 weeks after
EOT. This result is comparable to recent reports, with
graft rejection rates ranging from 0 to 4.2% (10,18,21).
The European Liver and Intestine Transplant Association
recommends careful monitoring of immunosuppression
levels during treatment and particularly after EOT, since
improved liver function can alter exposure to immuno-
suppressants (33).
In Brazil, HCV treatment is funded and provided by the
Ministry of Health. The real-life treatment experience of
Brazilian patients is of paramount importance to evaluate
the success of public health policies and the need for
incorporation of other therapeutic possibilities.
Limitations of this study include its observational
nature and small sample size, which hamper analyses
of factors associated with treatment failure and the role
of ribavirin for achieving SVR. The presence of universal
fibrosis staging prior to HCV treatment could allow analyses
of the relationships between fibrosis and virological
response and adverse effects. Even though it is not
necessary for treatment recommendation, the knowl-
edge of the fibrosis staging can be helpful in order to
determine which patients would benefit from the use of
RBV or 24 weeks of treatment, not to mention its role in
establishing the need for HCC surveillance. Tests for
resistance-associated variants could have been performed
to help analyze if the treatment failure observed was due to
antiviral resistance, which could influence the choice of
subsequent treatment for the patient. The short follow-up
after antiviral treatment did not allow any considerations on
the relationship between DAA therapy and HCC recur-
rence. Further studies with larger populations and longer
observation periods are necessary to clarify this matter.
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